TMA7

Across TCGA pan-cancer cohorts, TMA7 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of TMA7’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TMA7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TMA7 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

LIHC, KIRC, and BLCA are the cancer types where TMA7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMA7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.919	<.001	9	view →
KIRC	Female	III,IV	−0.577	<.001	9	view →
BLCA	All	IV	+1.031	.001	8	view →
BRCA	All	All	+0.280	<.001	6	view →
CHOL	Male	All	+1.104	<.001	4	view →
KICH	All	All	−0.680	<.001	4	view →
STAD	Female	All	+0.644	.033	3	view →
HNSC	Female	All	−0.385	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

TMA7–LIHC

Open the LIHC breakdown →